A Randomized Phase II, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of INC280 in Adult Patients With Advanced Hepatocellular Carcinoma After Progression or Intolerance to Sorafenib Treatment
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 15 Sep 2016
At a glance
- Drugs Capmatinib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors Novartis
- 30 Aug 2016 Status changed from suspended to withdrawn prior to enrolment.
- 13 Dec 2013 Planned End Date changed from 1 Mar 2016 to 1 Sep 2016 as reported by ClinicalTrials.gov.
- 13 Dec 2013 Planned initiation date changed from 1 Feb 2014 to 1 Mar 2014 as reported by ClinicalTrials.gov.